Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGPMA Accepted as Full Member of IGPA
December 10, 2007
- Another Reduction in Medical Fees Non Recommendable: Chuikyo
December 10, 2007
- Kobashou's Shareholders Approve Share Exchange with Mediceo
December 10, 2007
- ZERIA: Ethical Drugs Down, Consumer Healthcare Products Up
December 3, 2007
- OPINION／Why Japanese Executives Are Grossly Underpaid
December 3, 2007
- Fuso: First Operating, Ordinary Losses Since Listing
December 3, 2007
- TOPICS／CareNet, Recruit Start Career Support Services for Doctors
December 3, 2007
- Wakamoto: Rysmon TG Shows Strong Growth
December 3, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 3, 2007
- CMIC: Addition of CMIC SS CMO Boosts Sales, Profits
December 3, 2007
- GENERICS NEWS IN BRIEF
December 3, 2007
- EPS: CRO, SMO Businesses Drives Sales, Profits
December 3, 2007
- Gov't Appeals Asserting Legitimacy of Kongo Shinryo
December 3, 2007
- Diovan Remains No.1 for 6th Month in a Row: Rep Track Survey
December 3, 2007
- Kyowa Hakko and Kirin Pharma Are a Perfect Match: Dr Matsuda
December 3, 2007
- Wider Range of Drugs to Be Re-Priced in Next Price Revision
December 3, 2007
- Re-Pricing of ARBs May Be Necessary: Mr Niwa
December 3, 2007
- Council Calls For "Extraordinary NHI Drug Price Cuts"
December 3, 2007
- Re-Pricing Runs Counter to the Promotion of Innovation: Dr Aoki
December 3, 2007
- REGULATORY NEWS IN BRIEF
December 3, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…